Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + Bevacizumab + FOLFOX in MSS RAS-Mutated mCRC
NCT06218810Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in metastatic colorectal cancer (mCRC), sponsored by Fudan University. Started Jan 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06218810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218810.